Cboe UK GBp

AstraZeneca PLC (AZNL.XC)

10,758.00

+162.00

+(1.53%)

At close: May 2 at 4:29:58 PM GMT+1

AstraZeneca First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

AstraZeneca ( LON:AZN ) First Quarter 2025 Results Key Financial Results Revenue: US$13.6b (up 7.2% from 1Q 2024). Net...

Simply Wall St. yesterday

AZN

AZNCF
AstraZeneca (LSE:AZN) Announces Positive Results From Breztri Trials For Uncontrolled Asthma

AstraZeneca (LSE:AZN) recently announced phase III trial results for Breztri Aerosphere, its triple-combination asthma therapy, marking a milestone in improving care standards for asthma patients. This announcement comes amidst the company's robust Q1 2025 financial performance, which showed significant gains in sales, revenue, and net income. Meanwhile, the broader market rose by 1.8% last week, buoyed by positive macroeconomic indicators such as strong jobs data. AstraZeneca's share price...

Simply Wall St. 2 days ago

AZN

AZNCF
Here's what top C-suites are saying about tariffs

US President Trump's tariff policies have created a challenging environment for business leaders. Here's what some executives are saying about navigating tariffs, including CEOs from Coca-Cola (KO), Starbucks (SBUX), and AstraZeneca (AZN), and top executives at Meta (META), General Motors (GM), and Amazon (AMZN). To watch more expert insights and analysis on the latest market action, check out more Wealth here.

Yahoo Finance Video 2 days ago

AAPL

KO

AMZN
European Equities Close Sharply Higher in Friday Trading; Eurozone Inflation Unchanged at 2.2%

The European stock markets closed sharply higher in Friday trading as the Stoxx Europe 600 climbed 1

PREMIUM
MT Newswires 2 days ago

^GDAXI

^FTSE

^FCHI
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma

On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials assessed the efficacy and safety of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) compared with two fixed-dose, dual-combination therapies of budesonid (an ICS) and formoterol fumarate (LABA) and Symbicort pressurized metered-dose inhaler (pMDI). KALOS and LOGOS included approximately 4,400 randomized patients.

Benzinga 2 days ago

AZN
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.

Tempus AI is a leader in applying AI solutions to cancer diagnosis. The company announced a new platform for speeding up the discovery of new drug targets. Since it's still unprofitable, Tempus AI is an investment with a higher degree of risk.

Motley Fool 2 days ago

TEM

^GSPC

AZN
Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive Sales Growth

AMGN beats first-quarter estimates for earnings and sales. Sales of most of its products, Prolia, Xgeva, Repatha, Blincyto and Evenity beat estimates.

Zacks 2 days ago

AMGN

AZN
AstraZeneca’s triple-combo triumphs in two Phase III asthma trials

The company plans to submit the positive data to regulatory authorities for review.

Clinical Trials Arena 2 days ago

AZN

GLDAF
Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma

The FDA pushed back its decision date on Cytokinetics’ heart drug, while AstraZeneca got Phase 3 results that could help it expand use of a top drug.

BioPharma Dive 3 days ago

AZN

CYTK

PLRX
BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma

WILMINGTON, Del., May 02, 2025--Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (I

Business Wire 3 days ago

AZN

AZNCF
'Declare victory and move on': Eli Lilly CEO on Trump tariff threat

Eli Lilly CEO says Trump tariff threat has already achieved the goal of repatriating manufacturing in pharma.

Yahoo Finance 3 days ago

PFE

JNJ

RHHBF
Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View

IONS reports better-than-expected first-quarter results. The company raises its sales guidance for 2025 by more than 20% on the back of two new licensing deals.

Zacks 3 days ago

IONS

AZN
AstraZeneca quietly exits neuroscience

The company removed experimental drugs for Alzheimer’s, migraine and pain from its pipeline to focus more resources on “core therapeutic areas” and “high value” programs.

BioPharma Dive 3 days ago

AZN
3 UK Stocks Estimated To Be 21.1% To 46.6% Below Intrinsic Value

The United Kingdom's stock market has recently faced challenges, with the FTSE 100 closing lower due to weak trade data from China and declining commodity prices affecting major companies. In this environment of uncertainty, investors may be on the lookout for stocks that are undervalued relative to their intrinsic value, as these can present potential opportunities despite broader market fluctuations.

Simply Wall St. 4 days ago

AZN

AZNCF

BPT.L
Imfinzi approval positions AstraZeneca at forefront of perioperative MIBC

Sales are projected to reach $640 million by 2033 across the eight major markets.

Clinical Trials Arena 4 days ago

AZN
AstraZeneca’s Truqap fails in another Phase III trial

The FDA approved Truqap in November 2023 for the treatment of advanced HR-positive breast cancer.

Pharmaceutical Technology 5 days ago

AZN

GLDAF
AstraZeneca PLC (AZN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ...

AstraZeneca PLC (AZN) reports a robust start to 2025 with significant revenue and profit growth, while navigating competitive and regulatory headwinds.

GuruFocus.com 5 days ago

AZN
AstraZeneca Tops Earnings Views And Shares Rise Despite Cancer Miss

AstraZeneca stock rose moderately Tuesday despite a mixed first-quarter report and a setback for its experimental prostate cancer treatment.

Investor's Business Daily 5 days ago

AZN

AZNCF
Sector Update: Health Care Stocks Gain Late Afternoon

Health care stocks were rising late Tuesday afternoon, with the NYSE Health Care Index adding 1.2% a

PREMIUM
MT Newswires 5 days ago

AZN

GILD
AstraZeneca CEO calls for increased European investment in pharma

CEO Soriot said Europe must boost investment in pharma innovation or risk falling further behind the US in drug development.

Pharmaceutical Technology 5 days ago

AZN

Performance Overview

Return	AZNL.XC	FTSE 100 (^FTSE)
YTD	+2.92%	+5.18%
1-Year	-11.28%	+5.19%
3-Year	+0.76%	+13.94%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AstraZeneca PLC (AZNL.XC)

AstraZeneca First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

AstraZeneca (LSE:AZN) Announces Positive Results From Breztri Trials For Uncontrolled Asthma

Here's what top C-suites are saying about tariffs

European Equities Close Sharply Higher in Friday Trading; Eurozone Inflation Unchanged at 2.2%

AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma

Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.

Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive Sales Growth

AstraZeneca’s triple-combo triumphs in two Phase III asthma trials

Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma

BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma

'Declare victory and move on': Eli Lilly CEO on Trump tariff threat

Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View

AstraZeneca quietly exits neuroscience

3 UK Stocks Estimated To Be 21.1% To 46.6% Below Intrinsic Value

Imfinzi approval positions AstraZeneca at forefront of perioperative MIBC

AstraZeneca’s Truqap fails in another Phase III trial

AstraZeneca PLC (AZN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ...

AstraZeneca Tops Earnings Views And Shares Rise Despite Cancer Miss

Sector Update: Health Care Stocks Gain Late Afternoon

AstraZeneca CEO calls for increased European investment in pharma

Performance Overview